NO323003B1 - Farmasoytiske sammensetninger til svekkelse av de skadelige effekter av Tumor Nekrose Faktor-alfa (TNF-alfa) samt anvendelse derav. - Google Patents
Farmasoytiske sammensetninger til svekkelse av de skadelige effekter av Tumor Nekrose Faktor-alfa (TNF-alfa) samt anvendelse derav. Download PDFInfo
- Publication number
- NO323003B1 NO323003B1 NO19973812A NO973812A NO323003B1 NO 323003 B1 NO323003 B1 NO 323003B1 NO 19973812 A NO19973812 A NO 19973812A NO 973812 A NO973812 A NO 973812A NO 323003 B1 NO323003 B1 NO 323003B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- tnf
- tnfα
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims description 104
- 230000002939 deleterious effect Effects 0.000 title abstract description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title description 85
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 238000013270 controlled release Methods 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 6
- 208000035475 disorder Diseases 0.000 claims abstract description 6
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 28
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 21
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 15
- 230000009931 harmful effect Effects 0.000 claims description 13
- 239000007943 implant Substances 0.000 claims description 12
- 206010006895 Cachexia Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- -1 polyethylenes Polymers 0.000 claims description 8
- 206010003246 arthritis Diseases 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 229920000249 biocompatible polymer Polymers 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002732 Polyanhydride Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 229920002367 Polyisobutene Polymers 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 206010054094 Tumour necrosis Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000003313 weakening effect Effects 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 239000002861 polymer material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 20
- 239000000463 material Substances 0.000 abstract description 14
- 239000003446 ligand Substances 0.000 abstract description 7
- 238000006386 neutralization reaction Methods 0.000 abstract description 2
- 101500028161 Homo sapiens Tumor necrosis factor-binding protein 1 Proteins 0.000 description 57
- 102400000089 Tumor necrosis factor-binding protein 1 Human genes 0.000 description 57
- PFBLRDXPNUJYJM-UHFFFAOYSA-N tert-butyl 2-methylpropaneperoxoate Chemical compound CC(C)C(=O)OOC(C)(C)C PFBLRDXPNUJYJM-UHFFFAOYSA-N 0.000 description 57
- 241000699670 Mus sp. Species 0.000 description 43
- 102000005962 receptors Human genes 0.000 description 30
- 108020003175 receptors Proteins 0.000 description 30
- 239000005038 ethylene vinyl acetate Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 16
- 229920001432 poly(L-lactide) Polymers 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 14
- 229940098773 bovine serum albumin Drugs 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000009261 transgenic effect Effects 0.000 description 12
- 239000004005 microsphere Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 10
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 208000016261 weight loss Diseases 0.000 description 9
- 230000004580 weight loss Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 8
- 210000000544 articulatio talocruralis Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 208000010399 Wasting Syndrome Diseases 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000002917 arthritic effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000030852 Parasitic disease Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229920006237 degradable polymer Polymers 0.000 description 3
- 102000057041 human TNF Human genes 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- 101500028163 Homo sapiens Tumor necrosis factor-binding protein 2 Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102400000091 Tumor necrosis factor-binding protein 2 Human genes 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- XBBVURRQGJPTHH-DKWTVANSSA-N 2-hydroxyacetic acid;(2s)-2-hydroxypropanoic acid Chemical compound OCC(O)=O.C[C@H](O)C(O)=O XBBVURRQGJPTHH-DKWTVANSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000028570 negative regulation of locomotion Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000026498 progressive emaciation Diseases 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KVZLHPXEUGJPAH-QNDGGIRCSA-N rac-lactic acid Chemical compound C[C@@H](O)C(O)=O.C[C@H](O)C(O)=O KVZLHPXEUGJPAH-QNDGGIRCSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000807 solvent casting Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11283495A IL112834A (en) | 1995-03-01 | 1995-03-01 | Pharmaceutical compositions for controlled release of soluble receptors |
| PCT/US1996/003121 WO1996026738A1 (en) | 1995-03-01 | 1996-03-01 | Pharmaceutical compositions for controlled release of soluble receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO973812D0 NO973812D0 (no) | 1997-08-19 |
| NO973812L NO973812L (no) | 1997-11-03 |
| NO323003B1 true NO323003B1 (no) | 2006-12-18 |
Family
ID=11067150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19973812A NO323003B1 (no) | 1995-03-01 | 1997-08-19 | Farmasoytiske sammensetninger til svekkelse av de skadelige effekter av Tumor Nekrose Faktor-alfa (TNF-alfa) samt anvendelse derav. |
| NO20056197A NO328034B1 (no) | 1995-03-01 | 2005-12-27 | Farmasoytiske sammensetninger for kontrollert frigjoring av TNF-alfa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20056197A NO328034B1 (no) | 1995-03-01 | 2005-12-27 | Farmasoytiske sammensetninger for kontrollert frigjoring av TNF-alfa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6083534A (es) |
| EP (1) | EP0812208B1 (es) |
| JP (1) | JP4447052B2 (es) |
| KR (1) | KR100417650B1 (es) |
| CN (1) | CN1133464C (es) |
| AT (1) | ATE415941T1 (es) |
| AU (1) | AU692384B2 (es) |
| BR (1) | BR9607289A (es) |
| CA (1) | CA2213560C (es) |
| DE (1) | DE69637768D1 (es) |
| DK (1) | DK0812208T3 (es) |
| EA (1) | EA199700206A1 (es) |
| ES (1) | ES2318849T3 (es) |
| IL (1) | IL112834A (es) |
| MX (1) | MX9706626A (es) |
| NO (2) | NO323003B1 (es) |
| PT (1) | PT812208E (es) |
| UA (1) | UA44761C2 (es) |
| WO (1) | WO1996026738A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10510540A (ja) | 1994-12-12 | 1998-10-13 | オメロス メディカル システムズ，インコーポレーテッド | 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法 |
| US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
| US7067144B2 (en) * | 1998-10-20 | 2006-06-27 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| EP1206275B1 (en) * | 1998-11-05 | 2007-09-05 | Omeros Corporation | Irrigation solution and method for inhibition of pain and inflammation |
| US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| US7807211B2 (en) * | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
| EP1216037A2 (en) * | 1999-09-21 | 2002-06-26 | Emory University | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US8632845B2 (en) * | 2000-12-28 | 2014-01-21 | Abbott Cardiovascular Systems Inc. | Method of drying bioabsorbable coating over stents |
| AU2003209755B2 (en) * | 2002-02-06 | 2007-11-22 | Ares Trading S.A. | Tumor necrosis factor combined with interferon in demyelinating diseases |
| PT2561860T (pt) * | 2002-05-31 | 2018-05-08 | Titan Pharmaceuticals Inc | Dispositivo polimérico implantável para a libertação prolongada de buprenorfina |
| ES2601143T3 (es) * | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
| CN102772357B (zh) | 2003-03-31 | 2014-12-31 | 泰坦医药品公司 | 用于持续释放多巴胺受体激动剂的可植入聚合物装置 |
| US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| US20060046960A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
| CN1311818C (zh) * | 2004-11-22 | 2007-04-25 | 山东蓝金生物工程有限公司 | 一种抗实体肿瘤的药物组合物 |
| CA2588908C (en) * | 2004-11-29 | 2014-09-23 | Yeda Research And Development Co. Ltd | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
| US8128952B2 (en) * | 2005-01-12 | 2012-03-06 | Clemson University Research Foundation | Ligand-mediated controlled drug delivery |
| CN101500606B (zh) * | 2005-06-24 | 2013-12-04 | 杜克大学 | 基于热反应生物聚合物的直接药物送递系统 |
| US9012605B2 (en) | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
| US20090183503A1 (en) * | 2008-01-18 | 2009-07-23 | Alberto Verdesi | Exhaust apparatus |
| CA2721927C (en) | 2008-04-21 | 2014-01-28 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| US10092580B2 (en) | 2008-07-21 | 2018-10-09 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| CR20160147A (es) | 2011-03-25 | 2016-08-03 | Amgen Inc | Formulaciones de anticuerpos |
| US20150125471A1 (en) * | 2012-05-03 | 2015-05-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation |
| WO2014046631A1 (en) | 2012-09-19 | 2014-03-27 | Tezcaner Aysen | CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α |
| WO2015119653A1 (en) | 2014-02-04 | 2015-08-13 | Abbott Cardiovascular Systems Inc. | Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating |
| AU2015289874A1 (en) | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| US10611850B2 (en) | 2014-07-14 | 2020-04-07 | Amgen Inc. | Crystalline antibody formulations |
| US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
| US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
| EP3328898B8 (en) | 2015-07-28 | 2024-04-10 | 6452728 Canada Corp. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| JP5938762B1 (ja) | 2015-09-01 | 2016-06-22 | 日揮株式会社 | マイクロカプセル製剤及びその製造方法 |
| US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
| USD802757S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
| US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
| KR20200108873A (ko) | 2018-01-09 | 2020-09-21 | 오토노미, 인코포레이티드 | 성장 인자 귀 제제 |
| SG11202005947RA (en) | 2018-05-24 | 2020-07-29 | Celanese Eva Performance Polymers Corp | Implantable device for sustained release of a macromolecular drug compound |
| WO2019226519A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| US5114719A (en) * | 1987-04-29 | 1992-05-19 | Sabel Bernhard A | Extended drug delivery of small, water-soluble molecules |
| US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| IL98078A0 (en) * | 1991-05-07 | 1992-06-21 | Yeda Res & Dev | Pharmaceutical compositions comprising an anticytokyne |
| SE8804164A0 (sv) * | 1988-11-17 | 1990-05-18 | Per Prisell | Farmaceutisk beredning |
| US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5478564A (en) * | 1990-02-22 | 1995-12-26 | Teva Pharmaceutical Industries, Ltd. | Preparation of microparticles for controlled release of water-soluble substances |
| US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| US5330768A (en) * | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| IL99120A0 (en) * | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| WO1993015722A1 (en) * | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| WO1994006476A1 (en) * | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| EP0646000A4 (en) * | 1992-11-16 | 1997-05-02 | Univ Mercer | COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES. |
-
1995
- 1995-03-01 IL IL11283495A patent/IL112834A/xx not_active IP Right Cessation
-
1996
- 1996-01-03 UA UA97094438A patent/UA44761C2/uk unknown
- 1996-03-01 PT PT96909604T patent/PT812208E/pt unknown
- 1996-03-01 DE DE69637768T patent/DE69637768D1/de not_active Expired - Lifetime
- 1996-03-01 KR KR1019970706046A patent/KR100417650B1/ko not_active IP Right Cessation
- 1996-03-01 DK DK96909604T patent/DK0812208T3/da active
- 1996-03-01 EA EA199700206A patent/EA199700206A1/ru unknown
- 1996-03-01 BR BR9607289A patent/BR9607289A/pt not_active IP Right Cessation
- 1996-03-01 US US08/894,913 patent/US6083534A/en not_active Expired - Lifetime
- 1996-03-01 AT AT96909604T patent/ATE415941T1/de active
- 1996-03-01 AU AU53039/96A patent/AU692384B2/en not_active Expired
- 1996-03-01 MX MX9706626A patent/MX9706626A/es unknown
- 1996-03-01 WO PCT/US1996/003121 patent/WO1996026738A1/en active IP Right Grant
- 1996-03-01 EP EP96909604A patent/EP0812208B1/en not_active Expired - Lifetime
- 1996-03-01 CA CA2213560A patent/CA2213560C/en not_active Expired - Lifetime
- 1996-03-01 ES ES96909604T patent/ES2318849T3/es not_active Expired - Lifetime
- 1996-03-01 CN CNB961934379A patent/CN1133464C/zh not_active Expired - Lifetime
- 1996-03-01 JP JP52645796A patent/JP4447052B2/ja not_active Expired - Lifetime
-
1997
- 1997-08-19 NO NO19973812A patent/NO323003B1/no not_active IP Right Cessation
-
2005
- 2005-12-27 NO NO20056197A patent/NO328034B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20056197L (no) | 1997-11-03 |
| EP0812208A1 (en) | 1997-12-17 |
| UA44761C2 (uk) | 2002-03-15 |
| AU692384B2 (en) | 1998-06-04 |
| CN1133464C (zh) | 2004-01-07 |
| EP0812208A4 (en) | 2004-06-30 |
| US6083534A (en) | 2000-07-04 |
| IL112834A (en) | 2000-12-06 |
| PT812208E (pt) | 2009-02-06 |
| JP4447052B2 (ja) | 2010-04-07 |
| DK0812208T3 (da) | 2009-03-16 |
| CN1182369A (zh) | 1998-05-20 |
| DE69637768D1 (de) | 2009-01-15 |
| WO1996026738A1 (en) | 1996-09-06 |
| MX9706626A (es) | 1998-02-28 |
| KR19980702640A (ko) | 1998-08-05 |
| JPH11501306A (ja) | 1999-02-02 |
| NO973812L (no) | 1997-11-03 |
| ATE415941T1 (de) | 2008-12-15 |
| AU5303996A (en) | 1996-09-18 |
| ES2318849T3 (es) | 2009-05-01 |
| KR100417650B1 (ko) | 2004-05-20 |
| NO328034B1 (no) | 2009-11-16 |
| EA199700206A1 (ru) | 1998-02-26 |
| CA2213560A1 (en) | 1996-09-06 |
| IL112834A0 (en) | 1995-06-29 |
| NO973812D0 (no) | 1997-08-19 |
| BR9607289A (pt) | 1998-06-23 |
| CA2213560C (en) | 2010-08-24 |
| EP0812208B1 (en) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323003B1 (no) | Farmasoytiske sammensetninger til svekkelse av de skadelige effekter av Tumor Nekrose Faktor-alfa (TNF-alfa) samt anvendelse derav. | |
| Fujioka et al. | Protein release from collagen matrices | |
| Tabata et al. | Protein release from gelatin matrices | |
| Baldwin et al. | Materials for protein delivery in tissue engineering | |
| US7304035B2 (en) | Stimulation of bone growth with thrombin peptide derivatives | |
| CN107661490B (zh) | 包含格拉默或其药用盐的储药系统 | |
| CA1196864A (en) | Controlled release of injectable and implantable insulin compositions | |
| Langer et al. | Biocompatible controlled release polymers for delivery of polypeptides and growth factors | |
| TWI663985B (zh) | 用於持續釋放蛋白質之可生物降解的藥物傳遞系統 | |
| Eliaz et al. | Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo | |
| JP2007500723A (ja) | 肢体関節への高特異性サイトカイン抑制因子の嚢横断的投与 | |
| Zanella et al. | Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model | |
| von Knoch et al. | Suppression of polyethylene particle–induced osteolysis by exogenous osteoprotegerin | |
| Eliaz et al. | Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor | |
| JP2004203829A (ja) | Ｂｍｐを含有する徐放性製剤 | |
| Heller | POLY (ORTHO ESTERS) FOR THE PULSED AND CONTINUOUS DELIVERY OF PEPTIDES AND PROTEINS JORGE HELLER, ANN-FRANCE RIME, SUCHITRA S. RAO, BRUCE K. FRITZINGER AND STEVE Y. NG | |
| Omeis et al. | Prevention of cerebral vasospasm by local delivery of cromakalim with a biodegradable controlled-release system in a rat model of subarachnoid hemorrhage | |
| Langer | Biomaterials: new polymers and novel applications | |
| Babasola | Injectable delivery system based on 5-ethylene ketal-ϵ-caprolactone for the delivery of VEGF and HGF for treating critical limb ischemia | |
| Sondhof | The development of a biodegradable drug delivery system for orthopedic infection in the horse: in vitro and in vivo biocompatibility and gentamicin elution characteristics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |